Rauno Joks

Dr. Rauno Joks


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2011 in Pharmacological Research
Verified
Journal Article
Closed access
RJRauno Joks
Rauno Joks
HDHelen G. Durkin
Helen G. Durkin

1 January 2015 in Allergy & Rhinology
Verified
Journal Article
Open access
LYLihua Yang
Lihua Yang
SCStacy Clements
Stacy Clements
RJRauno Joks
Rauno Joks
Peanut (PN) and tree nut (TN) allergies are among the leading causes of fatal food-induced anaphylaxis and are increasing in prevalence, especially in children. Their cosensitization and concurrent clinical allergy have been understudied. This retrospective study investigated the correlation between PN and TN allergy, both in terms of in vitro sensitization (IVS) and clinical allergic manifestations. We conducted a retrospective medical record review at the Allergy Clinic at University Hospital of Brooklyn. Fourteen hundred six charts were reviewed, of which 76 (5.4%) had documented relevant clinical allergy: PN allergy but not TN allergy (n = 29) or TN allergy but not PN allergy (n = 11) or both (n = 30). Six patients with PN allergy but no TN exposure history were not included in the analysis. The majority of patients (67/76, 88.1%) had a concurrent history of asthma, rhinoconjunctivitis, or AD. Sensitivity of TN IVS predicting PN IVS was 38/39 (97%). Similarly, sensitivity of PN IVS predicting TN IVS was 38/42 (91%). Sensitivity of TN clinical allergy predicting PN allergy was 30/59 (51%). Sensitivity of PN clinical allergy predicting TN allergy was 30/41 (73%). The total number of organ systems involved in reported clinical reactions correlated with IVS to TN (p = 0.004) but not IVS to PN (p = 0.983). In summary, we found PN sensitization predicts TN sensitization in vitro, with lower predictability for clinical reactions.

24 February 2010 in International Immunology
Verified
Journal Article
Open access
PDF file
RJRauno Joks
Rauno Joks
TSTamar Smith-Norowitz
Tamar Smith-Norowitz
MNMaja Nowakowski
Maja Nowakowski
MBMartin H. Bluth
Martin H. Bluth
HDHelen G. Durkin
Helen G. Durkin
We previously reported that minocycline treatment of allergic asthmatic patients had oral steroid sparing effects and improved their clinical status and that minocycline suppressed in vitro induction of IgE responses by their PBMC. The effect of minocycline on human or animal IgE responses in vivo has not been studied. Allergic asthmatics (serum IgE: 505 ± 535 IU ml−1) were given minocycline (150 mg po to 250 mg po BID) as add-on therapy to standard care for up to 10 months; control subjects (IgE: 405 ± 472 IU ml−1) received standard care (n = 6 per group). Serum immunoglobulin (IgM, IgG, IgE and IgA) levels were determined monthly (Nephelometry, Unicap Total IgE Fluoroenzyme immunoassay). BALB/c mice (n = 6 per group) were injected intraperitoneally with benzylpenicilloyl14-Keyhole limpet hemocyanin (BPO14-KLH) in alum on days 0, 21 and 42, fed with minocycline or doxycycline (10–100 mg kg−1) on day 44 and numbers of BPO-specific IgG1, IgE and IgA antibody-forming cell (AFC) in mesenteric LN and spleen and serum immunoglobulin levels were determined on days 46–70 (enzyme-linked immunosorbent spot assay, ELISA). The ability of minocycline or doxycycline to suppress in vitro induction of murine memory IgE responses also was investigated. Minocycline strongly suppressed serum IgE levels of allergic asthmatics (9% per month) (P = 0.012). Minocycline (and doxycycline) also strongly suppressed peak murine IgE AFC and serum IgE responses (>95, ∼75%, respectively) and in vitro induction of memory IgE responses by murine mesenteric LN and spleen cells (>95%). Tetracycline suppression of all human and murine IgE responses was IgE isotype specific. Suppression of murine IgE responses in vivo was dose dependent and lasted 5–7 days.

1 September 2011 in Recent Patents on Inflammation & Allergy Drug Discovery
Verified
Journal Article
Closed access
PDF file
RJRauno Joks
Rauno Joks
HDHelen G. Durkin
Helen G. Durkin
There are no current therapies that specifically target IgE production in human allergic disease. We found that tetracyclines and chemically modified tetracyclines (CMT) that lack antibiotic activity prevent IgE production, making them ideal candidates for anti-allergy therapy. This is based on our findings that minocycline treatment of allergic asthmatic humans significantly improves their asthma symptoms, reduces their oral steroid requirements, and strongly suppresses their ongoing IgE responses. Tetracyclines and CMT also suppress ongoing IgE responses of BPO-KLH sensitized mice in vivo and in vitro and humans IgE responses in vitro. We also found that highly increased levels of phosphorylated p38 MAP kinase, but not phosphorylated JNK or ERK, are expressed by blood T and B cells and monocytes of allergic asthmatic humans. Levels of phosphorylated p38 MAP kinase, but not ERK or JNK, correlated with their IgE. Tetracyclines significantly suppressed expression of phosphorylated p38 MAP kinase by CD4+ and CD8+ T cells but not B cells or monocytes in vivo and in vitro. Our findings open the door to development of new drugs and patents, especially for CMTs that lack antibiotic activity (US 7649113), for treatment of human allergic disease.

1 June 2018 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
TSTamar A. Smith-Norowitz
Tamar A. Smith-Norowitz
DWDiana Weaver
Diana Weaver
YNYitzchok M. Norowitz
Yitzchok M. Norowitz
MHMargaret R. Hammerschlag
Margaret R. Hammerschlag
RJRauno Joks
Rauno Joks
SKStephan Kohlhoff
Stephan Kohlhoff

1 January 2010
Verified
Journal Article
Closed access
EHEhab Hassanain
Ehab Hassanain
JSJonathan Silverberg
Jonathan Silverberg
TSTamar A. Smith-Norowitz
Tamar A. Smith-Norowitz
SCSeto Chice
Seto Chice
MBMartin H. Bluth
Martin H. Bluth
TSTamar A Smith-Norowitz
Tamar A Smith-Norowitz